Clinical Trial Update: Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating the combination of everolimus and sorafenib for thyroid cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Drugs mentioned

• Afinitor (everolimus)
• Nexavar (Sorafenib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Thyroid Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING